NewsBite

Opinion

US success may lift Prima

Sarah Thompson and Stephen Shore
Updated
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Prima BioMed is likely to get a boost today after US Dendreon Corp, maker of the prostate-cancer drug Provenge, rose 39 per cent after reporting fourth-quarter revenue more than tripled from a year earlier.

Australian-listed Prima BioMed has developed a similar product to treat ovarian cancer.

Loading...
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

License article

Read More

Latest Street Talk

See all Street Talk

The Australian Financial Review Magazine

BOSS Financial Review

SPC CEO Robert Iervasi

Life & Leisure

Rich List

Nick Andrianakos, pictured in Greece’s Nafplio, where he had been building a hotel.

Original URL: https://www.afr.com/policy/us-success-may-lift-prima-20120106-iyzi3